Tracers / [67Cu]Cu-SARTATE
[67Cu]Cu-SARTATE
Also written as [Cu-67]Cu-SARTATE; SarTATE
- Radionuclide
- Cu-67 t½ 3708 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 2
What it is
- Compound class
- CB-TE1A1P-PEG4-LLP2A (VLA-4-targeting peptidomimetic conjugated to CB-TE1A1P chelator)
- Target / mechanism
- VLA-4 (integrin α4β1) PMID 39911068
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/cu64-sartate/">cu64-sartate</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
Need this precursor?We can point you to suppliers for [67Cu]Cu-SARTATE, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Cu-64. Compound class inferred from precursor name (not stated outright) -- PMID 39911068: 'CB-TE1A1P-PEG4-LLP2A (LLP2A) was kindly provided by AusPep (34).'. Stage set/updated at stage 23 from PMID 39911068: 'We used orthotopic syngeneic (i.e., B16-F10, B78, 4T1, GL261, TH-MYCN, and E2A-PBX1) and human (i.e., SK-MEL-37, 143B, and IMR-5) cancer models for in vivo PET/CT imaging and biodistribution studies.'.